Label: GLUCOHEPTONATE - calcium gluceptate injection, powder, lyophilized, for solution

  • NDC Code(s): 51808-213-01
  • Packager: AnazaoHealth Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

Drug Label Information

Updated 05/12

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Dear Medical Professional,

    Per your order, we have compounded Glucoheptonate as a sterile freeze-dried mixture. The characteristics of this preparation are

    Close
  • DESCRIPTION

    AnazaoHealth supplies compounded Glucoheptonate for the preparation of Tc 99m Glucoheptonate. Each vial contains 50 mg calcium glucoheptonate and 0.6 mg tin metal as stannous chloride. The vial is back filled with inert gas and may contain a partial vacuum.

    Close
  • CLINICAL PHARMACOLOGY

    When injected intravenously, Technetium Tc 99m Glucoheptonate is rapidly cleared from the blood. In patients with normal renal function, less than 15% of the initial activity remains in the blood after one hour. About 40% of the injected dose is excreted in the urine in one hour, while about 70% is excreted in 24 hours. In patients with renal disease, the blood clearance and urinary excretion of the radiopharmaceutical are delayed.

    Up to 15% of the injected dose is retained in the kidneys. The renal retention is greater in the cortex than in the medulla. The radiopharmaceutical may be bound to the proximal convoluted tubules, which are located primarily in the renal cortex.

    Technetium Tc 99m Glucoheptonate tends to accumulate in intracranial lesions that are associated with excessive neovascularity or an altered blood-brain barrier. The drug does not accumulate in the choroid plexus or salivary glands.

    Close
  • INDICATIONS AND USAGE

    Tc 99m Glucoheptonate may be used to image the kidney and brain and to assess renal and brain perfusion.

    Close
  • PREPARATION

    Preparation of Technetium Tc 99m Glucoheptonate is done by the following aseptic procedure:

    1. Waterproof gloves should be worn during the preparation procedure.
    2. Snap off the plastic lid and place room temperature reaction vial in an appropriate lead shield.
    3. Swab the rubber closure of the vial with a germicide.
    4. Inject 1 - 5 ml sterile, additive free sodium pertechnetate Tc 99m injection containing up to 5,920 MBq (160 mCi) into the vial. Be sure to maintain inert atmosphere in vial by introducing as little air as possible during reconstitution. NOTE: If sodium pertechnetate Tc 99m injection must be diluted, use only preservative free Sodium Chloride Injection USP.
    5. Secure the lead shield cover. Swirl the vial gently to mix contents and let stand 3 to 5 minutes prior to use.
    6. Record the date and time of preparation on a pressure-sensitive label.
    7. Affix pressure-sensitive label to shield.
    8. Examine vial contents; if the solution is not clear and free of particulate matter and/or discoloration on visual inspection, it should not be used.
    9. Measure the radioactivity by suitable calibration system and record prior to patient administration.
    10. Appropriate quality control is recommended.
    11. Injection should be administered within 12 hours of preparation.

    Storage and Handling

    This preparation should be stored at room temperature before and after reconstitution.

    Close
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Figure 1

    fb2f24ff-figure-01

    Close
  • INGREDIENTS AND APPEARANCE
    GLUCOHEPTONATE 
    glucoheptonate injection, powder, lyophilized, for solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51808-213
    Route of Administration INTRAVENOUS DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CALCIUM GLUCEPTATE (CALCIUM GLUCEPTATE) CALCIUM GLUCEPTATE 50 mg
    Inactive Ingredients
    Ingredient Name Strength
    STANNOUS CHLORIDE 0.6 mg
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:51808-213-01 1 in 1 KIT
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    Unapproved drug other 05/23/2012
    Labeler - AnazaoHealth Corporation (011038762)
    Establishment
    Name Address ID/FEI Business Operations
    AnazaoHealth Corporation 011038762 MANUFACTURE(51808-213)
    Close